As of January 13, 2020, each new patient registering for the first time at the Radboudumc is actively asked for consent to use his/her residual biomaterial, clinical imaging and medical data for scientific research. To date, there has been no major organizational obstacles in the implementation of this new consent procedure. However, its impact on available material and data is still under evaluation. In addition to quantitative analyses, qualitative research exploring underlying motivations of patients who consent or do not consent to the use of their material and data will also be performed. This feasibility study will be further expanded to assess the impact of the new consent procedure on vulnerable patient groups, i.e. children (<16 years old), acute care patients, and incapacitated patients.
For further information, please visit our website, “Use of medical data and leftover biomaterial” (available in Dutch only), or contact Dr. Jennifer Lutomski, project leader, at Jennifer.Lutomski@radboudumc.nl.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)19 July 2022
The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.read more